629 related articles for article (PubMed ID: 9422944)
1. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma.
Grover R; Ross DA; Wilson GD; Sanders R
Br J Plast Surg; 1997 Oct; 50(7):478-82. PubMed ID: 9422944
[TBL] [Abstract][Full Text] [Related]
2. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.
Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD
J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of c-myc oncogene expression in uveal melanoma.
Chana JS; Cree IA; Foss AJ; Hungerford JL; Wilson GD
Melanoma Res; 1998 Apr; 8(2):139-44. PubMed ID: 9610866
[TBL] [Abstract][Full Text] [Related]
4. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
5. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
7. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
Böni R; Bantschapp O; Müller B; Burg G
Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
9. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.
Pacifico MD; Grover R; Richman PI; Daley FM; Buffa F; Wilson GD
Plast Reconstr Surg; 2005 Feb; 115(2):367-75. PubMed ID: 15692338
[TBL] [Abstract][Full Text] [Related]
10. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
11. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
12. The prognostic importance of c-myc oncogene expression in head and neck melanoma.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Ann Plast Surg; 2001 Aug; 47(2):172-7. PubMed ID: 11506326
[TBL] [Abstract][Full Text] [Related]
13. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
[TBL] [Abstract][Full Text] [Related]
14. Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.
Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
J Eur Acad Dermatol Venereol; 2015 May; 29(5):912-8. PubMed ID: 25199412
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of oncogene expression in subungual melanoma.
Grover R; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1997 Jan; 50(1):15-9. PubMed ID: 9038509
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma.
Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB
Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853
[TBL] [Abstract][Full Text] [Related]
18. The Merkel cell carcinoma: survival and oncogene markers.
Jemec B; Chana J; Grover R; Grobbelaar AO
J Eur Acad Dermatol Venereol; 2000 Sep; 14(5):400-4. PubMed ID: 11305384
[TBL] [Abstract][Full Text] [Related]
19. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
Lipponen PK
J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
